Vetter Offers Sterile Water for Injection Syringes with Five Years Stability Data - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Vetter Offers Sterile Water for Injection Syringes with Five Years Stability Data
Vetter has ready-to-submit documentation for this service in Common Technical Document (CTD) formats for the US, Europe and Japan.


Vetter, a contract development and manufacturing organization, announced that it is offering filling services for sterile water for injection syringes with five years stability data. The CMO’s stability data and bracketing concept allows a longer shelf life for drugs and high flexibility while defining the filling volume. Vetter has ready-to-submit documentation for this service in Common Technical Document (CTD) formats for the US, Europe and Japan. Validation and stability data according to standard guidelines, such as the US Pharmacopeia, the European Pharmacopoeia and ICH, are also available.

The number of drugs that are sensitive to environmental influences is increasing. The formulations are often freeze dried to prolong shelf life and therefore require reconstitution in a suitable solvent before administration. Vetter filling service for syringes with sterile water for injection provides the solution for safe and simple reconstitution. The system contains the exact amount of solvent required by the customer to produce the required dosage, which helps assure that patients receive the exact amount of substance needed.

Vetter’s filling service for sterile water for injection syringes is available in 1.5 ml formats with a volume of 0.5 ml to 1.3 ml, as well as a 3 ml format with a volume of 1.4 ml to 3.0 ml. The syringe features Vetter’s V-OVS tamper-evident closure, which is designed to give a prefilled syringe system effective protection features. Vetter’s filling service comes with five years stability data and can manufacture batches of up to 140,000 pieces.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here